Search

everythinglearnresearchcommunity

for

Search:↓

Scientists made a mouse model of a serious skin cancer by changing skin cells with a virus and a specific gene, which is similar to the disease in humans.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

A mutation in the IKZF1 gene causes immune system overactivity, linked to autoimmune diseases like lupus.

Certain immune cells may cause hair loss by reacting to stressed hair follicles.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

IL-15 is key for T cell function and could help improve treatments for immune-related diseases.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

People with atopic dermatitis have more CD4+ T cells that respond to a certain bacterial lipid, which may play a role in the skin condition's inflammation.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

Targeting specific T cells may help treat alopecia areata.

The muscle damage was caused by T-cell large granular lymphocytic leukemia, not dermatomyositis.

ILC1-like cells may contribute to hair loss in alopecia areata and could be new treatment targets.

Activating TLR9 helps heal large wounds and regrow hair by involving a specific type of immune cell.

Cell-based therapy using specific immune cells may help treat alopecia areata by promoting hair regrowth.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Increasing regulatory T cells may help treat alopecia areata by reducing autoimmunity and promoting hair growth.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.

New findings suggest targeting IL-23 could treat psoriasis, skin cells can adapt to new roles, direct conversion of skin cells to blood cells may aid cell therapy, removing certain tumor cells could boost cancer immunotherapy, and melanoma may have many tumorigenic cells, not just cancer stem cells.

Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.

Activating TLR3 boosts autophagy gene expression in skin cells.

Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.

Targeting the AhR pathway may help treat alopecia areata.

Alopecia areata involves specific immune cells, offering potential treatment targets.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

Dormant melanoma cells in mice interact minimally with memory T cells due to a suppressive tumor environment.

Catalytic antibodies are early indicators and active participants in the development of systemic lupus erythematosus.